Searched for:
(1 - 8 of 8)
document
Trion, A. (author), de Maat, M.P.M. (author), Jukema, J.W. (author), van der Laarse, A. (author), Maas, M.C. (author), Offerman, E.H. (author), Havekes, L.M. (author), Szalai, A.J. (author), Princen, H.M.G. (author), Emeis, J.J. (author), TNO Kwaliteit van Leven (author)
Objective - C-reactive protein (CRP) has been associated with risk of cardiovascular disease. It is not clear whether CRP is causally involved in the development of atherosclerosis. Mouse CRP is not expressed at high levels under normal conditions and increases in concentration only several-fold during an acute phase response. Because the...
article 2005
document
Sakharov, D.V. (author), Jie, A.F.H. (author), Bekkers, M.E.A. (author), Emeis, J.J. (author), Rijken, D.C. (author), Gaubius Instituut TNO (author)
We present the first steps in the elaboration of an approach of extracellular matrix-targeted local drug delivery (ECM-LDD), designed to provide a high concentration, ubiquitous distribution, and long-term retention of a drug within the vessel wall after local intravascular delivery. The approach is based on the concept of a bifunctional drug...
article 2001
document
Yudkin, J.S. (author), Panahloo, A. (author), Stehouwer, C. (author), Emeis, J.J. (author), Bulmer, K. (author), Mohamed-Ali, V. (author), Denver, A.E. (author), Gaubius Instituut TNO (author)
Aims/hypothesis. Improved glycaemic control might reduce both microvascular and macrovascular complications of Type II diabetes (non-insulin-dependent) mellitus. To explore such possible mechanisms, we investigated the effects of intensive treatment on markers of endothelial dysfunction and of acute phase activation, using both sulphonylureas...
article 2000
document
Lansink, M. (author), Jong, M. (author), Bijsterbosch, M. (author), Bekkers, M. (author), Toet, K. (author), Havekes, L. (author), Emeis, J. (author), Kooistra, T. (author), Gaubius instituut TNO (author)
Several clinical studies have demonstrated an inverse relationship between circulating levels of estrogen and tissue-type plasminogen activator (t-PA). The present study was designed to test the hypothesis that estrogen lower plasma levels of t-PA by increasing its clearance from the bloodstream. 17α-Ethinyl estradiol (EE) treatment resulted in...
article 1999
document
Schalkwijk, C.G. (author), Poland, D.C.W. (author), van Dijk, W. (author), Kok, A. (author), Emeis, J.J. (author), Dräger, A.M. (author), Doni, A. (author), van Hinsbergh, V.W.M. (author), Stehouwer, C.D.A. (author), Gaubius instituut TNO (author)
Moderately increased plasma concentrations of C-reactive protein are associated with an increased risk of cardiovascular disease, C-reactive protein, its relation to a low degree of inflammatory activation and its association with activation of the endothelium have not been systematically investigated in Type I (insulin-dependent) diabetes...
article 1999
document
Jager, A. (author), van Hinsbergh, V.W.M. (author), Kostense, P.J. (author), Emeis, J.J. (author), Yudkin, J.S. (author), Nijpels, G. (author), Dekker, J.M. (author), Heine, R.J. (author), Bouter, L.M. (author), Stehouwer, C.D.A. (author), Gaubius instituut TNO (author)
Increased levels of von Willebrand factor (vWf) and C-reactive protein (CRP) predict cardiovascular mortality in selected populations. It is uncertain whether vWf and CRP predict mortality in a general population and whether vWf and CRP predict mortality through similar pathways. This study investigated the association of vWf and CRP with...
article 1999
document
Yudkin, J.S. (author), Stehouwer, C.D.A. (author), Emeis, J.J. (author), Coppack, S.W. (author), Gaubius instituut TNO (author)
C-reactive protein, a hepatic acute phase protein largely regulated by circulating levels of interleukin-6, predicts coronary heart disease incidence in healthy subjects. We have shown that subcutaneous adipose tissue secretes interleukin-6 in vivo. In this study we have sought associations of levels of C-reactive protein and interleukin-6 with...
article 1999
document
Noorman, F. (author), Barrett-Bergshoeff, M.M. (author), Bekkers, M. (author), Emeis, J.J. (author), Rijken, D.C. (author), Gaubius Instituut TNO (author)
Dextran is used during surgery as a prophylactic agent to prevent deep venous thrombosis. Recently it has been shown that dextran increases t-PA plasma concentrations in patients. As dextran is a potential ligand for the mannose receptor, we studied whether this glucose-polymer would be able to inhibit mannose receptor-mediated clearance of t-PA...
article 1997
Searched for:
(1 - 8 of 8)